CASRN: 2423014-07-5
Drug Levels and Effects
Summary of Use during Lactation
Emergency use authorization for sotrovimab has been withdrawn in the US because of its poor activity against some Omicron strains of SARS- CoV-2. Sotrovimab is a monoclonal antibody directed against the SARS-CoV-2 virus that causes COVID-19. No information is available on the clinical use of sotrovimab during breastfeeding. Because sotrovimab is a large protein molecule, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Similar anti-SARS-CoV-2 monoclonal antibodies were used during pregnancy and lactation in one mother with no adverse consequences.[1] Until more data become available, sotrovimab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
- 1.
- Ogawa E, Goto H, Ushimaru H, et al. Vaginal delivery after improvement in COVID-19 by monoclonal antibody treatment: A case report and literature review. J Infect Chemother. 2022;28:982–6. PMID. [PMC free article: PMC8898669] [PubMed: 35288022]
Substance Identification
Substance Name
Sotrovimab
CAS Registry Number
2423014-07-5
Drug Class
Breast Feeding
Lactation
Milk, Human
Antibodies, Monoclonal, Humanized
Antibodies, Viral
Antiviral Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
Publication Details
Publication History
Last Revision: February 15, 2023.
Copyright
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Publisher
National Institute of Child Health and Human Development, Bethesda (MD)
NLM Citation
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Sotrovimab. [Updated 2023 Feb 15].